- Home
- Publications
- Publication Search
- Publication Details
Title
DPP-4 Inhibitors in Clinical Practice
Authors
Keywords
-
Journal
POSTGRADUATE MEDICINE
Volume 121, Issue 6, Pages 70-100
Publisher
Informa UK Limited
Online
2009-12-02
DOI
10.3810/pgm.2009.11.2079
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug evaluation: Vildagliptin-metformin single-tablet combination
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
- (2009) Daniel M. Riche et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
- (2009) J. Rosenstock et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
- (2009) Debora Williams-Herman et al. CURRENT MEDICAL RESEARCH AND OPINION
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
- (2009) G. Bolli et al. DIABETES OBESITY & METABOLISM
- Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
- (2009) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- (2009) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
- (2009) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus
- (2009) Masatoshi Kikuchi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
- (2009) M. Goodman et al. HORMONE AND METABOLIC RESEARCH
- Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
- (2009) A. R. Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
- (2009) Bo Ahrén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Sitagliptin on the Pharmacokinetics of Simvastatin
- (2009) Arthur J. Bergman et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
- (2009) E.J. Verspohl PHARMACOLOGY & THERAPEUTICS
- Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
- (2009) Nancy Bohannon POSTGRADUATE MEDICINE
- Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes
- (2009) Janet B. McGill POSTGRADUATE MEDICINE
- Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
- (2008) Goutam C. Mistry et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- New treatments in type 2 diabetes: a focus on the incretin-based therapies
- (2008) Anthony H. Barnett CLINICAL ENDOCRINOLOGY
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pancreatic α-cell dysfunction in diabetes
- (2008) R. Burcelin et al. DIABETES & METABOLISM
- Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
- (2008) J.-F. Gautier et al. DIABETES & METABOLISM
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
- (2008) R. A. DeFronzo et al. DIABETES CARE
- Insulin Resistance and Hyperinsulinemia: Is hyperinsulinemia the cart or the horse?
- (2008) M. H. Shanik et al. DIABETES CARE
- Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database
- (2008) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia*
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
- (2008) R. Scott et al. DIABETES OBESITY & METABOLISM
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*
- (2008) A. J. Garber et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
- (2008) J. C. N. Chan et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
- (2008) Kenji Nonaka et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
- (2008) Viswanathan Mohan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
- (2008) C. Pan et al. DIABETIC MEDICINE
- Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus
- (2008) V. Fonseca et al. HORMONE AND METABOLIC RESEARCH
- Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin
- (2008) B. Göke et al. HORMONE AND METABOLIC RESEARCH
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
- (2008) Pei Hu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
- (2008) F. Xavier Pi-Sunyer POSTGRADUATE MEDICINE
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
- (2008) Debora Williams-Herman et al. BMC Endocrine Disorders
- Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia
- (2007) Andrea Mari et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects
- (2007) Yan-Ling He et al. JOURNAL OF CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started